Kendall Capital Partners is a Boston-based venture capital firm investing in early-to-commercial stage life sciences and healthcare companies, focusing on deep science, gene and cell therapies, next-gen immunotherapies, advanced drug delivery, and AI/computational biology.
57% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (57% of deals). Average disclosed round size is $26.8M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Professor George M. Church
General Partner & Investment Committee Member, Kendall Capital Partners
Professor Robert S. Langer
General partner and Investment Committee Member, Kendall Capital Partners
Neil Butler, PhD
Investment Associate
Victor Olmos, PhD
Investment Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Centivax | Series B | $37M | Mar 2026 |
| Centivax | Series A | $45M | Jul 2025 |
 EpiBone | Unknown | — | Nov 2024 |
| EEyenuk, Inc. | Series A | $26M | Oct 2022 |
| EEyenuk | Series A | $26M | Oct 2022 |
 Blu Wireless | Growth | $16.6M | — |
 Rejuvenate Bio | Series A | $10M | — |
Top Co-Investors
Last updated: 8 September 2026